{"id":21954,"date":"2022-07-21T10:21:16","date_gmt":"2022-07-21T08:21:16","guid":{"rendered":"https:\/\/idibell.cat\/?p=21954"},"modified":"2022-07-21T13:46:32","modified_gmt":"2022-07-21T11:46:32","slug":"atg-therapeutics-arrenca-amb-una-primera-ronda-de-financament-de-mes-de-mig-milio-deuros","status":"publish","type":"post","link":"https:\/\/idibell.cat\/2022\/07\/atg-therapeutics-arrenca-amb-una-primera-ronda-de-financament-de-mes-de-mig-milio-deuros\/","title":{"rendered":"AtG Therapeutics arrenca amb una primera ronda de finan\u00e7ament de m\u00e9s de mig mili\u00f3 d&#8217;euros"},"content":{"rendered":"<p><a href=\"https:\/\/www.atgtx.com\/\">AtG Therapeutics<\/a>, un nou actor de l&#8217;R+D a l&#8217;\u00e0mbit de l&#8217;oncologia, anuncia el seu llan\u00e7ament amb una primera ronda de finan\u00e7ament que puja a 556.000 euros a la primera fase. La ronda de finan\u00e7ament va ser recolzada per un fons d&#8217;inversi\u00f3 internacional <a href=\"https:\/\/bluegoosecap.com\/\">Blue Goose Capital<\/a>, dos grups de Business Angels a nivell nacional, <a href=\"https:\/\/wa4steam.com\/\">WA4STEAM<\/a> i el grup <a href=\"http:\/\/www.inveniam-group.com\">StapleCat\/Inveniam<\/a>, i tamb\u00e9 diversos cient\u00edfics internacionals d&#8217;alt renom.<\/p>\n<p>Fundada pels investigadors Oriol Casanovas, Gabriela Jim\u00e9nez juntament amb l&#8217;assessor internacional Bart Huisken, AtG Therapeutics desenvolupar\u00e0 una cartera de medicaments per al tractament de c\u00e0ncers avan\u00e7ats. Per aix\u00f2 comptar\u00e0 amb el suport d&#8217;un equip amb una \u00e0mplia experi\u00e8ncia consolidada a la ind\u00fastria farmac\u00e8utica i biotecnol\u00f2gica.<\/p>\n<p>L&#8217;empresa comen\u00e7ar\u00e0 treballant a dos programes; un d&#8217;un nou medicament centrat en una nova diana terap\u00e8utica, implicada en el metabolisme de les c\u00e8l\u00b7lules tumorals i un selector de pacients que permetr\u00e0 identificar els pacients que es beneficiaran del tractament. Dels quals, respectivament, l&#8217;<strong>AtG 153 <\/strong>ja en fase d&#8217;estudis precl\u00ednics amb models animals i <strong>AngioDxPredict<\/strong> es troba en fase de desenvolupament del prototip. La cartera inicial servir\u00e0 de base per a una expansi\u00f3 posterior cap al futur desenvolupament de programes innovadors de R+D per a diverses indicacions oncol\u00f2giques.<\/p>\n<p>&nbsp;<\/p>\n<h3>Els fundadors:<\/h3>\n<p><strong><em>Oriol Casanovas.<\/em><\/strong> Investigador biom\u00e8dic del Programa ProCURE (IDIBELL i ICO). Internacionalment reconegut pel seu ampli coneixement i experi\u00e8ncia en recerca b\u00e0sica i translacional de l&#8217;angiog\u00e8nesi tumoral i la resist\u00e8ncia terap\u00e8utica.<\/p>\n<p><strong><em>Gabriela Jim\u00e9nez.<\/em><\/strong> Farmac\u00e8utica i doctora en Biomedicina (UB) i Tech transfer leadership per la UPF, s&#8217;ha format a les escoles de negocis EADA i IESE, compta amb amplis coneixements cient\u00edfics i experi\u00e8ncia al m\u00f3n empresarial.<\/p>\n<p><strong><em>Bart Huisken.<\/em><\/strong> Experimentat emprenedor en s\u00e8rie, visionari, mentor de CEOs, consultor amb m\u00e9s de 25 anys d&#8217;experi\u00e8ncia a la ind\u00fastria que estableix noves empreses i unitats de negocis. Bart t\u00e9 un MBA de INSEAD.<\/p>\n<p>&nbsp;<\/p>\n<p>\u201c<em>Amb una cartera que, en un primer moment, se centra en tres c\u00e0ncers avan\u00e7ats, renal, colorectal i mama, no tenim cap dubte que AtG crear\u00e0 un valor significatiu en els pacients i en un sector amb una oportunitat de mercat existent<\/em>\u201d, assenyala <strong>Blue Goose Capital<\/strong>, Boston (MA).<\/p>\n<p>&#8220;<em>AtG Therapeutics encaixa perfectament amb els requisits dels projectes en qu\u00e8 volem invertir: clara innovaci\u00f3 STEAM, emprenedora a l&#8217;equip fundador, un equip solvent i un projecte ben constru\u00eft amb perspectives de futur<\/em>&#8221; assenyalen des de <strong>WA4STEAM<\/strong>.<\/p>\n<p>\u201c<em>Ens enorgulleix anunciar el llan\u00e7ament d&#8217;AtG Therapeutics<\/em> -apunta la <strong>Dra. Gabriela Jim\u00e9nez<\/strong>, cofundadora i CEO de la spin-off-. <em>Els actius d&#8217;alta qualitat de la nostra cartera de productes tenen el potencial de canviar la vida dels pacients sense alternatives terap\u00e8utiques eficaces<\/em>\u201d.<\/p>\n<p>\u201c<em>\u00c9s molt motivador i il\u00b7lusionant veure com la feina de tants anys de recerca ja est\u00e0 arribant a una fase en qu\u00e8 aviat es convertir\u00e0 en una realitat per als pacients amb c\u00e0ncer avan\u00e7at i que els ajudar\u00e0 a combatre aquesta malaltia<\/em>\u201d, comenta el <strong>Dr. Oriol Casanovas<\/strong> cofundador i CSO d&#8217;AtG Therapeutics.<\/p>\n<p>&#8220;<em>Hem contribu\u00eft a la creaci\u00f3 d&#8217;AtG per accelerar que els aven\u00e7os del grup de recerca del Dr. Casanovas centrat en el desenvolupament de ter\u00e0pies basades en la medicina de precisi\u00f3 ajudin els pacients que pateixen c\u00e0ncers avan\u00e7ats<\/em>&#8220;, afegeix el <strong>Dr. Gabriel Capell\u00e0<\/strong> director de l&#8217;IDIBELL.<\/p>\n<p>&nbsp;<\/p>\n<h3>Sobre AtG Therapeutics<\/h3>\n<p>AtG Therapeutics \u00e9s una companyia de creaci\u00f3 recent, d&#8217;IDIBELL i de l&#8217;ICO. Aquest projecte ha estat recolzat per diverses institucions de l&#8217;\u00e0mbit internacional i nacional entre elles: l&#8217;European Research Council (ERC), la Fundaci\u00f3 \u201cLa Caixa\u201d, l&#8217;Associaci\u00f3 Espanyola Contra el C\u00e0ncer (AECC), l&#8217;Institut de Salut Carles III i La Prospectiva en Salut a Espanya (FIPSE).<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p><em>L\u2019Institut d&#8217;Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL) \u00e9s un centre de recerca en biomedicina creat l\u2019any 2004. Est\u00e0 participat per l&#8217;Hospital Universitari de Bellvitge i l\u2019Hospital de Viladecans de l&#8217;Institut Catal\u00e0 de la Salut, l&#8217;Institut Catal\u00e0 d&#8217;Oncologia, la Universitat de Barcelona i l\u2019Ajuntament de l\u2019Hospitalet de Llobregat.<\/em><\/p>\n<p><em>L\u2019IDIBELL \u00e9s membre del Campus d&#8217;Excel\u00b7l\u00e8ncia Internacional de la Universitat de Barcelona HUBc i forma part de la instituci\u00f3 CERCA de la Generalitat de Catalunya. L&#8217;any 2009 es va convertir en un dels cinc primers centres d\u2019investigaci\u00f3 espanyols acreditats com a institut d\u2019investigaci\u00f3 sanit\u00e0ria per l\u2019Instituto de Salud Carlos III. A m\u00e9s, forma part del programa \u201cHR Excellence in Research\u201d de la Uni\u00f3 Europea i \u00e9s membre de EATRIS i REGIC. Des de l\u2019any 2018, l\u2019IDIBELL \u00e9s un Centro Acreditado de la Fundaci\u00f3n Cient\u00edfica AECC (FCAECC).<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>La spin-off sorgida de l&#8217;IDIBELL i de l&#8217;Institut Catal\u00e0 d&#8217;Oncologia desenvolupa noves alternatives terap\u00e8utiques per a c\u00e0ncers avan\u00e7ats i un sistema de cribratge d&#8217;aquests pacients.<\/p>\n","protected":false},"author":8,"featured_media":21956,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"default","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""}},"footnotes":""},"categories":[493],"tags":[],"publishpress_future_action":{"enabled":false,"date":"2024-05-04 10:46:20","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category"},"_links":{"self":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/21954"}],"collection":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/comments?post=21954"}],"version-history":[{"count":5,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/21954\/revisions"}],"predecessor-version":[{"id":21967,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/21954\/revisions\/21967"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media\/21956"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media?parent=21954"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/categories?post=21954"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/tags?post=21954"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}